Yes. Novartis's drug Ceritinib is actually a couple of steps behind Brig. You can't make comparison between the drugs at this point because the Novartis trial is for 1st line usage, in other words the patients haven't been compromised with any other drugs prior to this test.
Brig on the other hand had patients that already have failed many other drugs already.
The only data we have to compare to Novartis's trial would be the 8 patients from the phase 1/2 trial who were uncompromised. At last report only 2 of the 8 progressed at 24 months while all were alive at 24 months. Novartis's trial reported pfs at 16 months.
3 of these 8 patients obtained a CR which is very critical going forward.
As a note Ceritinib did have a encouraging result if the patient didn't have brain mets. (26.3 mos)
News 
Market Data 
Discover 
